Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity
about
Oxidative Stress in Placenta: Health and DiseasesSkepinone-L is a selective p38 mitogen-activated protein kinase inhibitorDifferential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss.Perspective on the discovery and scientific impact of p38 MAP kinase.Intracellular signal pathways: potential for therapies.A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis.Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as wellp38α regulates actin cytoskeleton and cytokinesis in hepatocytes during development and agingThe Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival.Measuring and interpreting the selectivity of protein kinase inhibitorsThe p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer."Go upstream, young man": lessons learned from the p38 saga.Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses.Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).System-based drug discovery within the human kinome.Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Extract from Acanthopanax senticosus prevents LPS-induced monocytic cell adhesion via suppression of LFA-1 and Mac-1.p38β MAP kinase as a therapeutic target for pancreatic cancer.A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins.Causal network analysis of head and neck keloid tissue identifies potential master regulators.Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta-stimulated human chondrocytes.Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment.More than just B-cell inhibition.A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8).NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production.OA10 is a novel p38alpha mitogen-activated protein kinase inhibitor that suppresses osteoclast differentiation and bone resorption.Alternative p38 MAPKs are essential for collagen-induced arthritis.
P2860
Q26773521-401404B1-B613-4DBB-98E0-88964C0611DBQ27676453-14744EB5-0976-4851-AC6F-83D20A88A92FQ30415395-F86C6EF6-2614-4B21-8308-144B6BCDCB6CQ34360512-09778D54-220B-40FA-8B4F-345DF89BC94DQ34551138-B21CE2D1-93BC-4D9C-B2A9-D755B9705813Q34881784-47AAFF41-C526-417F-958F-E169553638F0Q35751545-12B73B88-6CE1-4605-AC88-DBB744D64826Q36271777-28DAAC00-7C5B-43CA-9807-7D3D67D5D464Q37158987-458631FF-9207-4FD1-9BA4-0052E3EE7307Q37537075-D23FDE96-3D1D-413A-A3E1-276910FA55A9Q37620350-D4DDF23D-92E0-4092-8349-7961C232C03EQ37649076-AC489BAD-F49B-4A45-B62F-82827C5277D9Q37688086-8BA53B68-A67B-4732-B183-C8C84F58C391Q37776270-F6648476-B608-43BA-B8D1-07CA71DC18C1Q37955936-2A143892-565C-4E58-A4E8-7244ADE481EFQ38042726-59934197-97A3-4134-B820-4918175C678EQ38078271-39FCE685-C2E8-4F07-8FF3-88D52C56B351Q38697262-70F3FB21-DEF6-4E1B-B8AA-58AB3A6CEDB5Q39007004-2E0F1F37-B2FC-411C-98C9-8139B7F957F5Q39362199-B49AF611-E7A3-49AB-A263-ADF69EDAD95FQ39622833-572D4F0A-C55F-4DB0-8414-A0B55ED0ADDBQ39910050-044752F6-00EC-4564-BBC5-F3E87662D415Q40359435-399A7910-C278-442F-B59F-9C9F023CDA2DQ42429559-3654AACF-AFDB-45B7-B305-D8C063FF93C7Q42546841-81FDFE76-D423-4E49-A164-36BD60494979Q42933562-49F9F6C6-4509-48FE-9F65-390BA488A1ADQ43184375-DFE93327-EB3E-4159-897F-C96016B91466Q43279669-2C025E5F-024C-423A-A7DE-7892BAA847BEQ46982725-738E5764-24E8-4B92-8BAD-A1A3F581AFC2Q50701558-F8E6356F-3FD2-4581-9AA7-5313FC034596Q54356167-A886915E-79E0-4B54-A414-0BAA97E8464E
P2860
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@ast
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@en
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@nl
type
label
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@ast
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@en
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@nl
prefLabel
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@ast
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@en
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@nl
P2093
P3181
P356
P1476
Pamapimod, a novel p38 mitogen ...... is of efficacy and selectivity
@en
P2093
Anthony M Manning
Brian R Wong
David Leaffer
David M Goldstein
Deborah Phippard
Joseph Dal Porto
Karim Dabbagh
P3181
P356
10.1124/JPET.108.139006
P407
P577
2008-12-01T00:00:00Z